The immunopathophysiology of acute graft-versus-host-disease

Stem Cells

Volumn 14, Issue 5, 1996, Pages 473-489

  Ferrara, James L M ^b   Cooke, Kenneth R ^b   Pan, Luying ^b   Krenger, Werner ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

Bone marrow transplantation; Cytokines; Graft versus host disease; Review; Th1 Th2 cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN;

BONE MARROW TRANSPLANTATION; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HELPER CELL; IMMUNOPATHOLOGY; INFLAMMATION; REVIEW; T LYMPHOCYTE;

EID: 0029780327     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.140473     Document Type: Review

References (139)

1. Van Bekkum DW, De Vries MJ. Radiation Chimeras. London: Logos Press, 1967.
2. Billingham RE, Brent L. A simple method for inducing tolerance of skin homografts in mice. Transplant Bull 1957;4:67-71.
3. Korngold R, Sprent J. T cell subsets in graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J et al., eds. Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York: Marcel Dekker, 1990:31-50.
4. Kernan HNA, Collins NH, Juliano L et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-vs-host disease. Blood 1986;68:770-773.
5. Den Haan JM, Sherman NE, Blokland E et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476-1480.
6. Hess AD, Fischer AC. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation 1989;48:895-900.
7. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990;323:315-321.
8. Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of acute graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J et al., eds. Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York: Marcel Dekker, 1990:539-555.
9. Cooke KR, Kobzik L, Martin TR et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood 1996 (in press).
10. Piguet PF, Grau GE, Collart MA et al. Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab Invest 1989;61:37-45.
11. Sale GE, Shulman HM. The Pathology of Bone Marrow Transplantation. New York: Masson, 1984.
12. Beschorner W, Saral R, Hutchins G et al. Lymphocytic bronchitis associated with graft versus host disease in recipients of bone marrow transplants. N Engl J Med 1978;299:1030-1036.
13. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-2968.
14. Jadus MR, Wepsic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 1992;10:1-14.
15. Krenger W, Ferrara JLM. Dysregulation of cytokines during graft-versus-host disease. J Hematother 1996;5:3-14.
16. Xun CQ, Thompson JS, Jennings CD et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994;83:2360-2367.
17. Cavender DE, Haskard DO, Joseph B et al. Interleukin-1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. J Immunol 1986;136:203-207.
18. Chang RJ, Lee SH. Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of an Ia antigen on a murine macrophage cell line. J Immunol 1986;137:2853-2856.
19. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990;76:1867-1871.
20. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987;67:397-406.
21. Krensky AM, Weiss A, Crabtree G et al. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990;322:510-517.
22. Unanue ER, Allen PM. The basis of the immunoregulatory role of macrophages and other accessory cells. Science 1987;236:551-557.
23. June CH, Bluestone JA, Nadler LM et al. The B7 and CD28 receptor families. Immunol Today 1994;15:321-331.
24. Nishizuka Y. Studies and perspectives of protein kinase C. Science 1986;233:305-312.
25. Samelson LE, Patel MD, Weissman AM et al. Antigen activation of murine T cell induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell 1986;46:1083-1090.
26. Mosmann TR, Cherwinski H, Bond MW et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357.
27. + T cells secreting Th1 or Th2 cytokines. Immunity 1995;2:271-279.
28. Weiss A. T lymphocyte activation. In: Paul WE, ed. Fundamental Immunology. New York: Raven Press, 1989:359-384.
29. Hemler ME. Adhesive protein receptors on hematopoietic cells. Immunol Today 1988;9:109-113.
30. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
31. Swain SL, Bradley LM, Croft M et al. Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development. Immunol Rev 1991;123:115-144.
32. Salgame P, Abrams JS, Clayberger C et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991;254:279-282.
33. Seder RA, Boulay JL, Finkelman FD et al. CD8 T cells can be primed in vitro to produce IL-4. J Immunol 1992;148:1652-1656.
34. Doutrelepont JM, Moser M, Leo O et al. Hyper IgE in stimulatory graft-versus-host disease: role of interleukin-4. Clin Exp Immunol 1991;83:133-136.
35. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol 1993;23:333-337.
36. DeWit D, Van Mechelen M, Zanin C et al. Preferential activation of Th2 cells in chronic graft-versus-host disease. J Immunol 1993;150:361-366.
37. Garlisi CG, Pennline KJ, Smith SR et al. Cytokine gene expression in mice undergoing chronic graft-versus-host disease. Mol Immunol 1993;30:669-677.
38. Ghayur T, Seemayer TA, Kongshawn PAL et al. Graft-versus-host (GVH) reactions in the beige mouse: an investigation of the role of host and donor natural killer cells in the pathogenesis of GVH disease. Transplantation 1987;44:261-267.
39. Ferrara JLM, Guillen PF, van Dijken PJ et al. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation 1989;47:50-54.
40. Nestel FP, Price KS, Seemayer TA et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992;175:405-413.
41. Suzuki M, Suzuki Y, Ikeda H et al. Apoptosis of murine large intestine in acute graft-versus-host disease after allogeneic bone marrow transplantation across minor histocompatibility barriers. Transplantation 1994;57:1284-1287.
42. Krenger W, Falzarano G, Delmonte J et al. Interferon-γ suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 1996;88:1113-1121.
43. Falzarano G, Krenger W, Snyder KM et al. Suppression of B cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-α in mice with acute graft-versus-host disease. Blood 1996;87:2853-2860.
44. Hakim FT, Sharrow SO, Payne S et al. Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice injected with parental lymphocytes. J Immunol 1991;146:2108-2115.
45. Ringden O. Viral infections and graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J et al., eds. Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York: Marcel Dekker, 1990;467:31-50.
46. Van Bekkum DW, Roodenburg J, Heidt PJ et al. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974;52:401-404.
47. Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992;80:2668-2676.
48. Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol 1993;5:565-572.
49. Jadus MR, Peck AB. Lethal murine graft-versus-host disease in the absence of detectable cytotoxic T lymphocytes. Transplantation 1983;36:281-289.
50. Chao NJ. Cytokines. In: Chao NJ, ed. Graft-versus-Host Disease. Austin, TX: R.G. Landes Co., 1994:49-57.
51. Malkovsky M, Brenner MK, Hunt R et al. T cell-depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin-2. Cell Immunol 1986;103:476-480.
52. Theobald M, Nierle T, Bunjes D et al. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992;327:1613-1617.
53. Schwarer AP, Jiang YZ, Brookes PA et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993;341:203-205.
54. Ringden O. Cyclosporine in allogeneic bone marrow transplantation. Transplantation 1986;42:445-452.
55. Gluckman E, Devergie A, Lokiek F et al. Role of immunosuppressive drugs for prevention of graft-vs.-host disease alter human HLA-matched bone marrow transplantation. Transplant Proc 1987;19:61-65.
56. Ferrara JLM, Marion A, McIntyre JF et al. Amelioration of acute graft-versus-host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 1986;137:1874-1877.
57. Herve P, Wijdenes J, Bergerat JP et al. Treatment of corticosteroid-resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990;75:1017-1023.
58. Belanger C, Esperou-Bourdeau H, Bordigoni P et al. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant 1993;11:293-297.
59. Anasetti C, Martin PM, Hansen JA et al. A Phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 1990;50:49-54.
60. Sykes M, Romick ML, Hoyles KA et al. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med 1990;171:645-658.
61. + T cell activity. J Immunol 1993;150:197-205.
62. + cells while preserving CD4-and CD8-mediated graft-versus-leukemia effects. Blood 1994;83:2560-2569.
63. Szebeni J, Wang MG, Pearson DA et al. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host disease. Transplantation 1994;58:1385-1393.
64. Soiffer RJ, Murray C, Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted bone marrow transplantation. Blood 1992;79:517-526.
65. Troutt AB, Kelso A. Enumeration of lymphokine mRNA-containing cells in vivo in a murine graft-versus-host reaction using the PCR. Proc Natl Acad Sci USA 1992;89:5276-5280.
66. + T cells activated in a graft-versus-host reaction. J Immunol 1990;145:2167-2176.
67. Smith SR, Terminelli C, Kenworthy-Bott L et al. A study of cytokine production in acute graft-vs-host disease. Cell Immunol 1991;134:336-348.
68. Krenger W, Snyder K, Smith S et al. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 1994;58:1251-1257.
69. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995;155:585-593.
70. Wall DA, Hamberg SD, Reynolds DS et al. Immunodeficiency in graft-versus-host reaction. 1. Mechanism of immune suppression. J Immunol 1988;140:2970-2976.
71. Troutt AB, Maraskovsky E, Rogers LA et al. Quantitative analysis of lymphokine expression in vivo and in vitro. Immunol Cell Biol 1992;70:51-57.
72. Velardi A, Varese P, Terenzi A et al. Lymphokine production by T-cell clones after human bone marrow transplantation. Blood 1989;74:1665-1672.
73. Niederwieser D, Herold M, Woloszczuk W et al. Endogenous IFN-gamma during human bone marrow transplantation. Transplantation 1990;50:620-625.
74. Dickinson AM, Sviland L, Dunn J et al. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro skin explant model. Bone Marrow Transplant 1991;7:209-216.
75. Mowat A. Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology 1989;68:18-24.
76. Mason DW, Dallman M, Barclay AN. Graft-versus-host disease induces expression of Ia antigen in rat epidermal cells and gut epithelium. Nature 1981;293:150-151.
77. Huber C, Niederwieser D. Role of cytokines and major histocompatibility complex antigens in graft-versus-host disease: in vitro studies using T cell lines and keratinocytes or hemopoietic targets. Haematol Blood Trans 1990;33:652-654.
78. Wall DA, Sheehan KC. The role of tumor necrosis factor-alpha and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation 1994;57:273-279.
79. Klimpel GR, Annable CR, Cleveland MG et al. Immunosuppression and lymphoid hypoplasia associated with chronic graft-versus-host disease is dependent upon IFN-γ production. J Immunol 1990;144:84-93.
80. Huchet R, Bruley-Rosset M, Mathiot C et al. Involvement of IFN-gamma and transforming growth factor-beta in graft-vs-host reaction-associated immunosuppression. J Immunol 1993;150:2517-2524.
81. Holda JH, Maier T, Claman NH. Evidence that IFN-γ is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation 1988;45:772-777.
82. Pace JL, Russell SW. Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J Immunol 1981;126:1863-1867.
83. Gifford GE, Lohmann-Matthes M-L. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J Natl Cancer Inst 1987;78:121-124.
84. Brok HPM, Heidt PJ, van der Meide PH et al. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993;151:6451-6459.
85. Heremans H, Dijkmans R, Sobis H et al. Regulation by interferons of the local inflammatory response to lipopolysaccharide. J Immunol 1987;138:4175-4179.
86. + helper cells. Transplantation 1995;60:481-490.
87. Sykes M, Szot GL, Nguyen PL et al. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995;86:2429-2438.
88. Piguet PF. Tumor necrosis factor and graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J et al., eds. Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York: Marcel Dekker, 1990:255-276.
89. Tracey KJ, Beutler B, Lowry SF et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-474.
90. Piguet PF, Grau GE, Allet B et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987;166:1280-1289.
91. McCarthy PL, Abhyankar S, Neben S et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991;78:1915-1918.
92. Clark J, Hansen J, Hertz M et al. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993;147:1601-1606.
93. Holler E, Kolb HJ, Hintermeier-Knabe R et al. The role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 1993;25:1234-1236.
94. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990;75:1011-1016.
95. Herve P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992;81:1993-1999.
96. Bianco JJ, Appelbaum FR, Guiffre A et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991;78:1205-1211.
97. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-1652.
98. Abhyankar S, Gilliland DG, Ferrara JLM. Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation 1993;56:1518-1523.
99. Parkman R, Lenarsky C, Barrantes B et al. Cytokines versus cytotoxic T lymphocytes (CTL) in the pathogenesis of acute graft-versus-host disease (GVHD). J Cell Biochem 1992;16a:186.
100. Atkinson K, Matias C, Guiffre A et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991;77:1376-1382.
101. Hannum CH, Wilcox CJ, Arend WP et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-340.
102. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323:705-712.
103. Arend WP, Smith JMF, Janson RW et al. IL-1 receptor antagonist and IL-1-beta production in human monocytes are regulated differently. J Immunol 1991;147:1530-1536.
104. Culpepper J, Lee F. Glucocorticoid regulation of lymphokine production by murine T lymphocytes. In: Webb DR, Goeddel DV, eds. Lymphokines: Molecular Cloning and Analysis. New York: Academic Press, 1987:275-289.
105. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-1738.
106. Jolivet J, Corvan KH, Curt G et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-1104.
107. Poynton CH. T cell depletion in bone marrow transplantation. Bone Marrow Transplant 1988;3:265-279.
108. Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T-cells from marrow. J Exp Med 1978;148:1687-1698.
109. Pietryga DW, Blazar BR, Soderling CC et al. The effect of T subset depletion on the incidence of lethal graft-versus-host disease in a murine major-histocompatibility-complex-mismatched transplantation system. Transplantation 1987;43:442-445.
110. Soderling CC, Song CW, Blazar BR et al. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants. J Immunol 1985;135:941-946.
111. Gale RP. T cells, bone marrow transplantation and immunotherapy: use of monoclonal antibodies in immune interventions in disease. Ann Intern Med 1987;106:257.
112. Gale RP, Reisner Y. Graft rejection and graft-versus-host disease: mirror images. Lancet 1986;1:1468-1470.
113. Vallera DA, Blazar BR. T cell depletion for graft-versus-host disease prophylaxis. A perspective on engraftment in mice and humans. Transplantation 1989;47:751-760.
114. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-814.
115. Truitt RL, LeFever AV, Shih CCY et al. Graft-versus-leukemia effect. In: Burakoff SJ, Deeg HJ, Ferrara J et al., eds. Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York: Marcel Dekker, 1990:177-204.
116. Sosman JA, Oettel KR, Smith SD et al. Specific recognition of human leukemic cells by allogeneic T cells. II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated non-leukemic cells. Blood 1990;75:2005-2016.
117. Sullivan KM, Witherspoon RP, Storb R et al. Prednisone and azathioprine compared to prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72:546-554.
118. Vossen JM, Heidt PJ. Gnotobiotic measures for the prevention of acute graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J et al., eds. Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York: Marcel Dekker, 1990:403-413.
119. Storb R, Prentice RL, Buckner CD et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983;308:302-307.
120. Kurrle E, Bhaduri S, Heimpel H et al. The efficiency of strict reverse isolation and antimicrobial decontamination in remission induction therapy of acute leukemia. Blut 1980;40:187-195.
121. Buckner CD, Clift RA, Sanders JE et al. Protective environment for marrow transplant recipients: a prospective study. Ann Int Med 1978;89:893-901.
122. Moore KW, O'Garra AO, De Waal Malefyt R et al. Interleukin-10. Annu Rev Immunol 1993;11:165-190.
123. Blazar BR, Taylor PA, Smith S et al. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995;85:842-851.
124. Swain SL, Weinberg AD, English M et al. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990;145:3796-3806.
125. Fowler DH, Kurasawa K, Husebekk A et al. Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. J Immunol 1994;152:1004-1011.
126. Krenger W, Cooke KR, Sonis ST et al. Transplantation of polarized type 2 donor T cells reduces systemic graft-versus-host disease induced by minor histocompatibility antigens. Transplantation 1996 (in press).
127. Dreger P, Suttorp M, Haferlach T et al. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993;81:1404-1409.
128. Russell NH, Hunter A, Rogers S et al. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993;341:1482.
129. Sasaki A, Tsukaguchi M, Hirai M et al. Transplantation of allogeneic peripheral blood stem cells after myeloablative treatment of a patient in blastic crisis of chronic myelocytic leukemia. Am J Haematol 1994;47:45-49.
130. Molina L, Chabannon C, Viret F et al. Granulocyte colony-stimulating factor-mobilized allogeneic peripheral blood stem cells for rescue graft failure after allogeneic bone marrow transplantation in two patients with acute myeloblastic leukemia in first complete remission. Blood 1995;85:1678-1679.
131. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:1655-1658.
132. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allograft. Blood 1995;85:1659-1665.
133. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgrastim (granulocyte colony-stimulating factor). Blood 1995;85:1666-1672.
134. Russell JA, Luider J, Weaver M et al. Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors. Bone Marrow Transplant 1995;15:111-115.
135. Martinez JA, Picon I, Carral A et al. Allogeneic peripheral blood progenitor cells mobilized by G-CSF (filgrastim) for a second transplant in a patient with acute myeloid leukemia in relapse. Bone Marrow Transplant 1995;15:149.
136. Tanaka J, Imamura M, Zhu X et al. Potential benefit of recombinant human granulocyte colony-stimulating-mobilized peripheral blood stem cells for allogeneic transplantation. Blood 1994;84:3595-3596.
137. Bensinger WI, Clift RA, Anasetti C et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. STEM CELLS 1996;14:90-105.
138. Pan L, Delmonte J, Jalonen CK et al. Pretreatment of donors with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type 2 cytokine production and reduces severity of experimental graft versus host disease. Blood 1995;86:4422-4429.
139. Pan L, Bressler KR, Cooke KR et al. Long-term engraftment, graft-versus-host disease, and immunologic reconstitution following experimental transplantation of allogeneic peripheral blood cells from G-CSF treated donors. Biol Blood Marrow Transplant 1996 (in press).